Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,397,759 papers from all fields of science
Search
Sign In
Create Free Account
FOLFOXIRI protocol
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (5)
Antineoplastic Combined Chemotherapy Protocols
Camptothecin
Fluorouracil
Leucovorin
Expand
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
I. Yıldız
,
H. Taskaynatan
,
+6 authors
M. Tarhan
2018
Corpus ID: 80035739
2017
2017
Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group.
D. Rossini
,
R. Moretto
,
+17 authors
A. Falcone
2017
Corpus ID: 80364236
3542Background: FOLFOXIRI plus bev is regarded by international guidelines as a valuable option in the first-line tx of mCRC pts…
Expand
2016
2016
TRIBE : la quadrithérapie FOLFOXIRI + bévacizumab, un nouveau standard en première ligne du cancer colorectal métastatique ?
L. Verlingue
,
D. Malka
2016
Corpus ID: 78744233
Le groupe italien GONO avait montre voici bientot 10 ans, avant l’ere des therapies ciblees, la superiorite d’une…
Expand
2013
2013
[Therapeutic strategy for recurrent gastric cancer and efforts aimed at finding a cure].
M. Asayama
,
T. Yamada-murano
,
H. Hara
,
A. Ooki
,
T. Yoshii
,
K. Yamaguchi
Gan to kagaku ryoho. Cancer & chemotherapy
2013
Corpus ID: 27129266
Recurrent gastric cancer, in general, is an incurable systemic disease for which the standard of care is systemic chemotherapy…
Expand
2008
2008
Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab
G. Masi
,
F. Loupakis
,
+7 authors
A. Falcone
2008
Corpus ID: 74046458
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required